Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematology
•
Diabetes
•
Endocrinology
Do you routinely monitor INR when starting GLP1 R agonist therapy on patients taking warfarin?
Related Questions
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
Should we recommend SGLT2i initiation at discharge to all patients hospitalized with acute myocardial infarction?
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
Can a patient with a PMHx of pancreatic injury or disease (i.e. blunt trauma, recurrent pancreatitis) take a GLP-1 agonist safely in the setting of morbid obesity and type 2 diabetes?
When should metformin be stopped before surgery and when is it considered safe to resume?
How do you adjust your HbA1c goal for managing diabetes in elderly patients with multiple chronic illnesses but no limitations in performing self-care tasks?
What are the potential causes for significant discrepancies between predicted A1c by Dexcom CGM and standard serum A1c by lab draw?
What is your approach to addressing severe dawn phenomenon in your patients with diabetes?
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
What is the clinical importance of differentiating between impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) states?
